INTEGRA LIFESCIENCES HOLDINGS CORP (IART) Form 8-K — Oct 19, 2026
$IARTForm 8-KItems 1.01, 1.02, 2.03, 7.01, 9.01Filed Oct 19, 2026, 4:20 PM ET0001193125-26-425271Original filing
Integra LifeSciences entered into an amended and restated credit agreement on October 19, 2026, making up to $1.65 billion available through a $600 million revolver, a $600 million Term Loan A (both five-year), and a $450 million Term Loan B (seven-year), with Bank of America as administrative agent. The same day, the company closed a private offering of $450 million of 9.500% senior secured notes due November 1, 2033, guaranteed on a senior secured basis by its wholly-owned domestic subsidiaries and secured by first-priority liens on substantially all assets.
Key figures
- Debt Amount
- $1.65 billion credit agreement ($600M revolver, $600M Term Loan A, $450M Term Loan B) plus $450 million senior secured notes
- Interest Rate
- 9.5
- Maturity Date
- November 1, 2033 (Notes); five years for Revolving and Term Loan A facilities, seven years for Term Loan B
- Term loan a
- $600 million
- Term loan b
- $450 million
- Notes coupon
- 9.500%
- Equity clawback
- up to 40% of notes at 109.500%
- Notes principal
- $450 million
- Repaid facilities
- $1.3 billion revolver and $775 million term loan due March 24, 2028
- Revolving facility
- $600 million
- Term loan b spread
- 4.25% over Term SOFR
- Commitment fee range
- 0.20%-0.35%
- Change of control put
- 101% of principal
- Revolver tla spread initial
- 3.00% over Term SOFR
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.